What Cimplrx does

Cimplrx (legal name: CIMPLRX) is a South Korea-based private drug discovery company founded in 2017 that develops and commercializes an Explainable Artificial Intelligence (XAI) platform branded CEEK-CURE. The platform is composed of two architectural layers: CEEK (Create ExplainablE Knowledge), a user interface for analyzing and visualizing results, and CURE (Collect and Uncover RElationships), a server-side XAI engine that handles machine learning requests. CEEK-CURE is delivered as four integrated workflow modules—Target Based Hit Identification (UniProt-driven), Compound Based Hit Identification (seed-compound driven across six chemical spaces), Lead Optimization with color- and size-coded contribution explanations, and Mechanism of Action (MoA) Identification—supported by visualization tools including parallel coordinates, chord diagrams, dendrograms, heatmaps, and interactive scatter plots for structure-activity relationship analysis.

The company's stated value proposition is to compress drug development timelines from the industry-standard 10+ years to 1–2 years and reduce costs by 15–30%, a claim sourced from third-party reporting rather than audited disclosures. Cimplrx monetizes through B2B professional services and joint research agreements with pharmaceutical and biotech partners, with no public pricing model or disclosed contract values. Its named customer base spans prior collaborations with Bristol-Myers Squibb (combinatorial chemical library design and HTS data analysis), Amgen (discovery and preclinical data analysis), CHDI (medicinal chemistry CRO management), and the University of North Carolina at Chapel Hill (ML via web application); current active co-development is centered on a 2025 joint research agreement with Dong-A ST, alongside multi-party collaborations with XtalPi and Gradiant Bioconvergence targeting cancer, brain diseases, immune/inflammatory diseases, and CNS disorders.

The company is privately held, headquartered at 18F, 282 Hagui-ro, Dongan-gu, Anyang-si, Gyeonggi-do, Korea, and has raised approximately $4.4M in disclosed funding as of October 2020 from Atinum Partners, Company K Partners, and Korea Investment & Securities, with additional backing from Aventures, BNK VC, KoreAsset, and Prodigy. No patents, management team bios, headcount disclosures, or audited revenue figures were available in the input materials.

Name

Cimplrx

Legal name

CIMPLRX

Website

https://cimplrx.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Cimplrx is a South Korea-based private drug discovery company that builds the CEEK-CURE Explainable AI platform for pharmaceutical and biotech partners. It offers hit identification, lead optimization, and mechanism-of-action modules through B2B joint research agreements.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Software

NAICS

Software Publishers (5132)

SIC

Services-Prepackaged Software (7372), Services-Computer Integrated Systems Design (7373)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• AI drug discovery
• Explainable AI platform
• Pharmaceutical R&D software
• Computational drug design
• Medicinal chemistry analytics

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. AI Drug Discovery Services: CIMPLRX provides AI-powered drug discovery services to pharmaceutical and biotech companies through joint research agreements and partnerships. The company participates in the full R&D process from candidate substance evaluation through preclinical and clinical development toward commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Cimplrx builds and operates CEEK-CURE, an Explainable AI (XAI) platform for drug discovery that combines a user-interface visualization layer (CEEK) with a server-side XAI engine (CURE). The platform runs supervised and unsupervised machine learning models on compound-target relationship data to perform target-based and compound-based hit identification, lead optimization, and mechanism-of-action identification for pharmaceutical and biotech partners. Cimplrx delivers these capabilities via joint research agreements with pharma/biotech companies.

Product overview

CIMPLRX is a drug discovery company operating as a single unified platform product built around its proprietary Explainable AI (XAI) engine called CEEK-CURE. The platform consists of two core components: CEEK (Create ExplainablE Knowledge), the user interface for analysis and visualization, and CURE (Collect and Uncover RElationships), the server-side XAI engine. The platform offers four integrated modules for drug discovery workflows: Target Based Hit Identification (using UniProt IDs to design compounds), Compound Based Hit Identification (using seed compounds across 6 chemical spaces), Lead Optimization (with explainable filtering), and Mechanism of Action Identification. The platform also provides visualization tools including parallel coordinates, chord diagrams, dendrograms, heatmaps, scatter plots, and clustering/diversity analysis tools.

Differentiator

Problem solved

Functional benefit

Brands

• CEEK-CURE: Explainable AI platform for drug discovery. CEEK (Create ExplainablE Knowledge) is the user interface for analyzing and visualizing results, while CURE (Collect and Uncover RElationships) is the XAI engine on the server side.

Products and services

• CEEK-CURE Explainable AI Platform An in-house Explainable AI platform for drug discovery offered by Cimplrx to pharmaceutical and biotech clients. CEEK (Create ExplainablE Knowledge) provides the analysis and visualization user interface, while CURE (Collect and Uncover RElationships) is the server-side XAI engine that handles machine learning requests. The platform supports target-based hit identification, compound-based hit identification, lead optimization, and mechanism-of-action identification with explainable visualizations.
• AI Drug Discovery Joint Research Services Collaborative drug discovery services delivered to pharmaceutical and biotech partners through joint research agreements, where Cimplrx applies CEEK-CURE to discover and develop new drug candidates through the candidate evaluation, preclinical, and clinical development stages.

Quantifiable outcome

• Reduces drug development timeline from over 10 years to 1–2 years
• +1 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Dong-A STcoreStrategic or Co-development PartnerDong-A ST, a Korean pharmaceutical company headquartered in Seoul, partnered with CIMPLRX for AI-based new drug development. The collaboration targets cancer, brain diseases, immune/inflammatory diseases, and CNS disorders, leveraging CIMPLRX's CEEK-CURE platform for automated drug discovery.
• UNC at Chapel HillminorStrategic or Co-development PartnerPrior collaboration for Machine Learning Via Web Application development.
• Bristol-Myers SquibbminorStrategic or Co-development PartnerPrior collaboration for Combinatorial Chemical Library Design and HTS Data Analysis & Visualization.
• AmgenminorStrategic or Co-development PartnerPrior collaboration for Discovery & Preclinical Data Analysis & Visualization.
• CHDIminorStrategic or Co-development PartnerPrior collaboration for Medicinal Chemistry CRO Management.
• Gradiant BioconvergencecoreStrategic or Co-development PartnerPartnered with Dong-A ST and CIMPLRX in a multi-party collaboration for AI-based new drug development targeting cancer, brain diseases, immune/inflammatory diseases, and CNS disorders.
• XtalPicoreStrategic or Co-development PartnerUS-based AI company partnered with Dong-A ST and CIMPLRX for AI-based new drug development, contributing AI technologies including organoid analysis, genomic big data, and automated drug discovery platforms.

Scale indicators2 records

Expansion highlights4 records

Direct peers

• XtalPi: XtalPi is an AI-driven drug discovery company combining physics-based modeling, AI, and high-throughput experimentation. It is explicitly named as a strategic partner in CIMPLRX's 2025 Dong-A ST alliance, operating in the same AI drug discovery category with overlapping target/lead-optimization capabilities.
• Schrödinger: Schrödinger provides physics-based and AI-augmented computational drug discovery software (e.g., LiveDesign) used by pharma for hit ID, lead optimization, and MoA analysis. It directly overlaps with CIMPLRX's target-based hit ID, lead optimization, and MoA modules on a platform-plus-services basis.
• Exscientia: Exscientia is a pioneer in AI-driven small-molecule drug discovery, offering end-to-end design-to-clinic capabilities through its Centaur platform. Both firms target pharma partnerships for AI-generated candidates and compete for similar enterprise design/development deals.
• Recursion Pharmaceuticals: Recursion combines high-throughput biology, automated wet labs, and ML foundation models for drug discovery. Its platform competes with CIMPLRX's CEEK-CURE for pharma/biotech partnerships seeking AI-native discovery engines.
• Insitro: Insitro applies machine learning to disease biology, target discovery, and small-molecule design through partnerships with pharma. It overlaps with CIMPLRX's discovery-platform model and targets the same enterprise buyer set.
• Atomwise: Atomwise uses AI (AtomNet) for structure-based small-molecule hit identification and lead optimization, primarily in early-stage discovery partnerships with pharma and biotech. It is directly comparable to CIMPLRX's target-based and compound-based hit ID modules.
• BenevolentAI: BenevolentAI applies AI to scientific knowledge graphs and target identification/drug discovery, offering a platform-plus-portfolio model. Its target ID and MoA-style inference work overlaps substantively with CIMPLRX's modules.

Emerging players

• Iambic Therapeutics: Iambic builds AI-driven platforms (e.g., NeuralPLexer, IAMBIC NIM) for structure-based drug design and target prediction. It overlaps with CIMPLRX in AI-native lead optimization and target-based design but is more focused on its own pipeline assets.
• Genesis Therapeutics: Genesis Therapeutics develops AI foundation models (e.g., Dynamic Pocket Discovery) for structure-based drug design. It is an emerging player in the same AI-led small-molecule discovery category as CIMPLRX, competing for pharma design partnerships.

Broad incumbents

• Isomorphic Labs: Isomorphic Labs, Alphabet's commercial spin-out, applies DeepMind's protein-modeling and AI drug design capabilities to pharma partnerships. It is a broad incumbent in AI drug discovery competing for the same enterprise design-and-development budgets as CIMPLRX.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cimplrx